Join FDA on July 9 for a Patient-Focused Drug Development meeting for Chronic Pain - Drug Information Update

News & Events > Public Meeting on Patient-Focused Drug Development for Chronic Pain

On July 9, 2018, the U.S. Food and Drug Administration (FDA) is hosting a public meeting on Patient-Focused Drug Development for Chronic Pain at its White Oak campus in Maryland. FDA is interested in hearing patients’ perspectives on chronic pain, views on treatment approaches, and challenges or barriers to accessing treatments for chronic pain. FDA is particularly interested in hearing from patients who experience chronic pain that is managed with analgesic medications such as opioids, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants; other medications; and non-pharmacologic interventions or therapies. Please register early to attend the meeting in person or view the live webcast. 

 

For more information, please visit: Patient-Focused Drug Development.

Meeting Information

On July 9, 2018, FDA is hosting a public meeting on Patient-Focused Drug Development for Chronic Pain. FDA is interested in hearing patients’ perspectives on chronic pain, views on treatment approaches, and challenges or barriers to accessing treatments for chronic pain. FDA is particularly interested in hearing from patients who experience chronic pain that is managed with analgesic medications such as opioids, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants; other medications; and non-pharmacologic interventions or therapies.

This website will be updated as meeting materials are developed. 

Date:

July 9, 2018

Time:

10:00 a.m. - 4:00 p.m. (registration will begin at 9:00am)

Location:

FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B & C (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA’s White Oak campus)

Registration:

To register for this meeting, visit: Public Meeting on Patient-Focused Drug Development for Chronic Pain

We recommend early registration for the meeting.

Related Information

• CDER Patient Focused Drug Development
• Enhancing Benefit-Risk Assessment in Regulatory Decision-Making